News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

CytRx Corporation (CYTR)’s Aldoxorubicin (INNO-206) Clinical Data to Be Featured at the ESMO 2012 Congress


8/7/2012 10:25:22 AM

LOS ANGELES--(BUSINESS WIRE)--CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical company specializing in oncology, announced that favorable results from its Phase 1b/2 clinical trial with its tumor-targeting doxorubicin conjugate aldoxorubicin (formerly known as INNO-206) primarily in patients with advanced soft tissue sarcoma will be featured in a poster presentation at the ESMO (European Society of Medical Oncology) 2012 Congress being held September 28 - October 2 in Vienna, Austria.

Read at BioSpace.com

Related News

comments powered by Disqus
   
Sarcoma

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES